Assistant Professor, Oncologic Sciences, USF-Morsani
Oncology
Dr. Gregory M. Springett, MD
|
|
Give Review
Gregory Springett practices Oncology. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care Gregory Springett is also a published MD. He has 36 paper published. The most recent paper is: A family of cAMP-binding proteins that directly activate Rap1. He accepts Medicare.
Publications
- A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia.
- Outcomes of resected pancreatic Cancer in patients age ≥70.
- Resected pancreatic Cancer outcomes in the elderly.
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors.
- Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenoCarcinoma.
- Comparative long-term outcomes of upfront resected pancreatic Cancer after preoperative biliary drainage.
- Novel Pancreatic Cancer Vaccines Could Unleash the Army Within.
- Adjuvant radiotherapy and lymph node dissection in pancreatic Cancer treated with surgery and chemotherapy.
- Dendritic Cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
- Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated.
- Effects of a Brief Multimedia Psychoeducational Intervention on the Attitudes and Interest of Patients With Cancer Regarding Clinical Trial Participation: A Multicente...
- Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors.
- Leukocyte adhesion deficiency-I variant syndrome (LAD-Iv, LAD-III): Molecular characterization of the defect in an index family.
- Discovery of a novel proteasome inhibitor selective for Cancer cells over non-transformed cells.
- Borderline resectable pancreatic Cancer: on the edge of survival.
- A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
- Pancreatic Cancer presenting as a Sister Mary Joseph's nodule: case report and update of the literature.
- Lysophosphatidic acid acyltransferase-beta is a prognostic marker and therapeutic target in gynecologic malignancies.
- Non-kinase second-messenger signaling: new pathways with new promise.
- Role of the WT1 tumor suppressor in murine hematopoiesis.
- Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma.
- A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraDuctal papillary m...
- Lysophosphatidic Acid Acyltransferase Beta Regulates mTOR Signaling.
- Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic Cancer.
- CA 19-9 as a biomarker in advanced pancreatic Cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
- Re-planning for compensator-based IMRT with original compensators.
- Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies.
- A family of cAMP-binding proteins that directly activate Rap1.
- A Rap guanine nucleotide exchange factor enriched highly in the Basal ganglia.
- Genetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patients.
- Substance use among the mentally ill: prevalence, reasons for use, and effects on illness.
- Association Analysis of adenosine A1 receptor gene (ADORA1) polymorphisms with schizophrenia in a Japanese population.
- Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenoCarcinoma: a double-blind randomised phase 3 study.
- Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.
Schools
Harvard Medical School
University Of Maryland Medical System
SloanKettering Medical Center
Weill Medical College Cornell University
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Memorial Sloan-Kettering Cancer Center -
University of Maryland -
Harvard Medical School
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1023023652 | |
| NPPES Provider LastName | SPRINGETT | |
| NPPES Provider FirstName | GREGORY | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 724.0 | |
| Distinct Opioid Count | 6.0 | |
| Opioid Claim Count | 109.0 | |
| Percent Opioid Claims | 15.06 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1023023652 |
| Last Name Of The Provider | SPRINGETT |
| First Name Of The Provider | GREGORY |
| View All |
Similar Doctors
|
Dr. Larry Kvols, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Ragini Kudchadkar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William S. Dalton, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Eduardo M. Sotomayor, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Richard H. Kim, MD |